Table of Contents
International Scholarly Research Notices
Volume 2014 (2014), Article ID 487101, 7 pages
http://dx.doi.org/10.1155/2014/487101
Research Article

Development and Validation of an Affinity Chromatography-Protein G Method for IgG Quantification

1Department of Quality Control, Center of Molecular Immunology, 11600 Havana, Cuba
2Biochemistry Laboratory, Quality Control Department, Center of Molecular Immunology, 11600 Havana, Cuba

Received 15 May 2014; Accepted 30 July 2014; Published 27 October 2014

Academic Editor: Qi Zhang

Copyright © 2014 Lesly Paradina Fernández et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Cedeño-Arias, C. E. Rengifo, Y. R. Batista, E. R. Calzado, and T. Rodríguez, “Immunohistochemical evaluation of H-R3 a novel humanized monoclonal antibody that neutralizes the EGF-receptor,” Applied Immunohistochemistry and Molecular Morphology, vol. 15, no. 2, pp. 213–219, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. L. E. M. Fernández, D. E. Kalume, L. Calvo, M. Fernández Mallo, A. Vallin, and P. Roepstorff, “Characterization of a recombinant monoclonal antibody by mass spectrometry combined with liquid chromatography,” Journal of Chromatography B, vol. 752, no. 2, pp. 247–261, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Mateo, E. Moreno, K. Amour, J. Lombardero, W. Harris, and R. Pérez, “Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity,” Immunotechnology, vol. 3, no. 1, pp. 71–81, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Crombet-Ramos, J. Rak, R. Pérez, and A. Viloria-Petit, “Antiproliferative, antiangiogenic and proapoptotic activity of H-R3: a humanized anti-EGFR antibody,” International Journal of Cancer, vol. 101, no. 6, pp. 567–575, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Talavera, R. Friemann, S. Gómez-Puerta et al., “Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation,” Cancer Research, vol. 69, no. 14, pp. 5851–5859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Beck, M. Bussat, N. Zorn et al., “Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells,” Journal of Chromatography B, vol. 819, no. 2, pp. 203–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Montesino, L. Calvo, A. Vallin, P. M. Rudd, D. J. Harvey, and J. A. Cremata, “Structural characterization of N-linked oligosaccharides on monoclonal antibody Nimotuzumab through process development,” Biologicals, vol. 40, no. 4, pp. 288–298, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Gaza-Bulseco, K. Hickman, S. Sinicropi-Yao, K. Hurkmans, C. Chumsae, and H. Liu, “Effect of the conserved oligosaccharides of recombinant monoclonal antibodies on the separation by protein A and protein G chromatography,” Journal of Chromatography A, vol. 1216, no. 12, pp. 2382–2387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Beck, E. Wagner-Rousset, D. Ayoub, A. van Dorsselaer, and S. Sanglier-Cianférani, “Characterization of therapeutic antibodies and related products,” Analytical Chemistry, vol. 85, no. 2, pp. 715–736, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Crombet, R. Pérez, A. Lage, M. Osorio, and T. Cruz, “Anticuerpo monoclonal humanizado h-R3: un nuevo concepto terapéutico para el tratamiento del cáncer avanzado,” Biotecnología Aplicada, vol. 20, pp. 33–51, 2003. View at Google Scholar
  11. C. Lam, E. Bouffet, and U. Bartels, “Nimotuzumab in pediatric glioma,” Future Oncology, vol. 5, no. 9, pp. 1349–1361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Perez and E. Moreno, “EGFR-targeting therapy as an evolving concept: learning from Nimotuzumab clinical development,” Chinese Clinical Oncology, pp. 1–10, 2013. View at Google Scholar
  13. ICH Q8 (R2), “Pharmaceutical Development,” 2009.
  14. S. Grotefend, L. Kaminski, S. Wroblewitz et al., “Protein quantitation using various modes of high performance liquid chromatography,” Journal of Pharmaceutical and Biomedical Analysis, vol. 71, pp. 127–138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Horak, A. Ronacher, and W. Lindner, “Quantification of immunoglobulin G and characterization of process related impurities using coupled Protein A and size exclusion high performance liquid chromatography,” Journal of Chromatography A, vol. 1217, no. 31, pp. 5092–5102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Amersham Biosciences, Ed., Affinity Chromatography: Principles and Methods, Freiburg, Germany, AD, 2002.
  17. Z. Yan and J. Huang, “Cleaning procedure for protein G affinity columns,” Journal of Immunological Methods, vol. 237, no. 1-2, pp. 203–205, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. A. C. Grodzki and E. Berenstein, “Antibody purification: affinity chromatography—protein A and protein G Sepharose,” Methods in Molecular Biology, vol. 588, pp. 33–41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. G. A. Shabir, “Validation of high-performance liquid chromatography methods for pharmaceutical analysis: understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization,” Journal of Chromatography A, vol. 987, no. 1-2, pp. 57–66, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. ICH Q2 (R1), “Validation of Analytical Procedures: Text and Methodology,” 2005.
  21. Applied Biosystems, “Columns for protein A and G affinity chromatography,” Operating Instructions, 2002, https://www3.appliedbiosystems.com/cms/groups/psm_support/documents/generaldocuments/cms_041641.pdf.
  22. Y. Vander Heyden, K. Luypaert, C. Hartmann, D. L. Massart, J. Hoogmartens, and J. de Beer, “Ruggedness tests on the high-performance liquid chromatography assay of the United States Pharmacopeia XXII for tetracycline hydrochloride. A comparison of experimental designs and statistical interpretations,” Analytica Chimica Acta, vol. 312, no. 3, pp. 245–262, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Vander Heyden, F. Questier, and D. L. Massart, “A ruggedness test strategy for procedure related factors: experimental set-up and interpretation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 17, no. 1, pp. 153–168, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Vander Heyden, F. Questier, and L. Massart, “Ruggedness testing of chromatographic methods: selection of factors and levels,” Journal of Pharmaceutical and Biomedical Analysis, vol. 18, no. 1-2, pp. 43–56, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Vander Heyden, A. Nijhuis, J. Smeyers-Verbeke, B. G. M. Vandeginste, and D. L. Massart, “Guidance for robustness/ruggedness tests in method validation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 24, no. 5-6, pp. 723–753, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Ermer and J. H. Miller, Eds., Method Validation in Pharmaceutical Analysis: A Guide to Best Practice, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2005.
  27. “Analytical method validation and transfer for Biotechnology products,” Tech. Rep. 57, PDA, 2012.
  28. FDA—Center for Drug Evaluation and Research, Reviewer Guidance. Validation of Chromatographic Methods, 1994.
  29. “Chromatography,” United States Pharmacopoeia 35 NF 30, Chapter 621, 2012.
  30. J. Ermer, “Validation in pharmaceutical analysis. Part I: an integrated approach,” Journal of Pharmaceutical and Biomedical Analysis, vol. 24, no. 5-6, pp. 755–767, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. U.S. Department of Health and Human Services; Food and Drug Administration Center for Drug Evaluation and Research Center for Veterinary Medicine, “Bioanalytical Method Validation,” Guidance for Industry, 2001.